Chenodeoxycholic Acid

Chenodeoxycholic acid (CDCA) is a primary bile acid synthesized in the liver from cholesterol. It is the most abundant bile acid in human bile and plays a critical role in lipid digestion and absorption. This product is supplied as a white to off-white crystalline powder with ≥98% purity (HPLC), specifically graded for pharmaceutical and research applications.

CDCA is used as an active pharmaceutical ingredient (API) in the treatment of gallstones (cholelithiasis) and is also a key intermediate in the synthesis of other bile acids like ursodeoxycholic acid (UDCA). Its amphipathic nature makes it valuable in formulation science, particularly for enhancing drug solubility and bioavailability.

Synonimy: Chenodeoxycholic acid, CDCA, 3α,7α-Dihydroxy-5β-cholanic acid, 5β-Cholanic acid-3α,7α-diol, Chenodiol, Chenix, 474-25-9

Zastosowania

• API for gallstone dissolution therapy (pharmaceutical formulations)
• Starting material for semi-synthetic bile acid derivatives (e.g., UDCA)
• Research reagent in lipid metabolism and bile acid signaling studies
• Excipient or solubilizer in drug delivery systems

Jakość i dokumentacja

Every batch is tested for assay (HPLC ≥98%), loss on drying (≤1.0%), heavy metals (≤10 ppm), and residual solvents. Full COA, MSDS, and TDS are available on request. Stability data can be provided for qualification purposes.

Opakowania i zaopatrzenie

Standardowe opakowania: 1 kg, 5 kg, 25 kg. Możliwość dostosowania opakowań oraz dostaw luzem. Produkty dostępne w magazynie wysyłamy w ciągu 3–5 dni. Minimalna wielkość zamówienia (MOQ) od 1 kg. W sprawie cen, próbek lub zamówień hurtowych prosimy o kontakt z naszym działem sprzedaży.

Zapytanie ofertowe

• Nasz adres: 280 Main Street, Xi’an, Shaanxi, Chiny
• LyvBio Sp. z o.o. — E-mail: info@lyvbio.com